Intravenous immunoglobulin may reduce relapse frequency in neuromyelitis optica

Viswanathan S 1 , Wong AH 2 , Quek AM 3 , Yuki N 4

Affiliations 

  • 1 Department of Neurology, Kuala Lumpur Hospital, Malaysia. Electronic address: shivenda70@yahoo.com
  • 2 Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. Electronic address: mdcwhyi@nus.edu.sg
  • 3 Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. Electronic address: Amy_QUEK@nuhs.edu.sg
  • 4 Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. Electronic address: mdcyuki@nus.edu.sg
J Neuroimmunol, 2015 May 15;282:92-6.
PMID: 25903734 DOI: 10.1016/j.jneuroim.2015.03.021

Abstract

To evaluate the use of intravenous immunoglobulin (IVIG) in preventing relapses in patients with neuromyelitis optica (NMO) and its spectrum disorders (NMOSDs).

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications